Success Metrics

Clinical Success Rate
86.8%

Based on 33 completed trials

Completion Rate
87%(33/38)
Active Trials
10(18%)
Results Posted
85%(28 trials)
Terminated
5(9%)

Phase Distribution

Ph phase_2
24
42%
Ph phase_1
9
16%
Ph early_phase_1
1
2%
Ph not_applicable
2
4%
Ph phase_3
3
5%
Ph phase_4
14
25%

Phase Distribution

10

Early Stage

24

Mid Stage

17

Late Stage

Phase Distribution53 total trials
Early Phase 1First-in-human
1(1.9%)
Phase 1Safety & dosage
9(17.0%)
Phase 2Efficacy & side effects
24(45.3%)
Phase 3Large-scale testing
3(5.7%)
Phase 4Post-market surveillance
14(26.4%)
N/ANon-phased studies
2(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.6%

33 of 42 finished

Non-Completion Rate

21.4%

9 ended early

Currently Active

10

trials recruiting

Total Trials

57

all time

Status Distribution
Active(10)
Completed(33)
Terminated(9)
Other(5)

Detailed Status

Completed33
Recruiting7
Terminated5
unknown5
Withdrawn4
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
57
Active
10
Success Rate
86.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.9%)
Phase 19 (17.0%)
Phase 224 (45.3%)
Phase 33 (5.7%)
Phase 414 (26.4%)
N/A2 (3.8%)

Trials by Status

terminated59%
completed3358%
unknown59%
active_not_recruiting35%
recruiting712%
withdrawn47%

Recent Activity

Clinical Trials (57)

Showing 20 of 57 trialsScroll for more
NCT06918990Phase 1

Treatment of Antibody-Mediated Rejection (ABMR) With CarBel

Recruiting
NCT01729494Phase 4

Belatacept Early Steroid Withdrawal Trial

Completed
NCT04827979Phase 1

Daratumumab and Belatacept for Desensitization

Completed
NCT06478017Phase 2

Belatacept in Heart Transplantation

Recruiting
NCT04877288Phase 3

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting
NCT06291077Phase 4

Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>

Recruiting
NCT05708534

Evolution of CMV Antiviral T-cell Immunity Over the Next Six Months Initiation of Treatment With Belatacept.

Active Not Recruiting
NCT06055608Phase 2

Advancing Transplantation Outcomes in Children

Recruiting
NCT05669001Phase 2

A Study of TCD601 in de Novo Renal Transplant Recipients

Completed
NCT02310867Phase 2

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

Recruiting
NCT05017545Phase 1

Carfilzomib and Belatacept for Desensitization

Active Not Recruiting
NCT03504241Phase 1

Tolerance by Engaging Antigen During Cellular Homeostasis

Completed
NCT04786067Phase 4

Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

Completed
NCT04477629Phase 2

Belatacept in De Novo Heart Transplantation

Recruiting
NCT04955366Phase 2

Abatacept Conversion in Kidney Transplantation

Active Not Recruiting
NCT04046549Phase 2

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Completed
NCT04066114Phase 1

Treg Modulation With CD28 and IL-6 Receptor Antagonists

Completed
NCT06307808

Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination

Unknown
NCT02213068Phase 4

Belatacept 3 Month Post Transplant Conversion Study

Completed
NCT01953120Phase 4

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
57